Effects of antacids and food on absorption of famotidine. 1987

J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
Merck Sharp and Dohme Research Laboratories, West Point, PA 19486.

The effect of a high potency antacid and food on the bioavailability of famotidine was studied in 17 healthy volunteers in an open randomized three-way cross-over trial. After an overnight fast, famotidine was administered to each subject as follows: 40 mg famotidine orally alone; 40 mg orally with antacid; and 40 mg orally with a standard breakfast. Coadministration of the antacid caused a small but significant reduction in the maximum plasma concentration (Cmax) of famotidine from 81.1 +/- 54.2 to 60.8 +/- 21.6 ng ml-1 (P less than 0.05) and a small decrease in the area under plasma concentration-time curve [AUC] from 443.3 +/- 249.2 to 355.0 +/- 125.1 ng ml-1 h (P greater than 0.05). However, there was only a minimal effect of food on these parameters; the Cmax and [AUC] were 81.6 +/- 29.6 ng ml-1 and 434.8 +/- 145.9 ng ml-1 h, respectively.

UI MeSH Term Description Entries
D007408 Intestinal Absorption Uptake of substances through the lining of the INTESTINES. Absorption, Intestinal
D008297 Male Males
D005260 Female Females
D005502 Food Substances taken in by the body to provide nourishment. Foods
D006635 Histamine H2 Antagonists Drugs that selectively bind to but do not activate histamine H2 receptors, thereby blocking the actions of histamine. Their clinically most important action is the inhibition of acid secretion in the treatment of gastrointestinal ulcers. Smooth muscle may also be affected. Some drugs in this class have strong effects in the central nervous system, but these actions are not well understood. Antihistaminics, H2,H2 Receptor Blockader,Histamine H2 Antagonist,Histamine H2 Blocker,Histamine H2 Receptor Antagonist,Histamine H2 Receptor Antagonists,Histamine H2 Receptor Blockader,Histamine H2 Receptor Blockaders,Antagonists, Histamine H2,Blockaders, Histamine H2 Receptor,H2 Receptor Blockaders,Histamine H2 Blockers,Receptor Antagonists, Histamine H2,Receptor Blockaders, H2,Antagonist, Histamine H2,Blockader, H2 Receptor,Blockaders, H2 Receptor,Blocker, Histamine H2,Blockers, Histamine H2,H2 Antagonist, Histamine,H2 Antagonists, Histamine,H2 Antihistaminics,H2 Blocker, Histamine,H2 Blockers, Histamine,Receptor Blockader, H2
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000863 Antacids Substances that counteract or neutralize acidity of the GASTROINTESTINAL TRACT. Alkalinizing Agent,Antacid,Alkalinizing Agents,Agent, Alkalinizing,Agents, Alkalinizing
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D013844 Thiazoles Heterocyclic compounds where the ring system is composed of three CARBON atoms, a SULFUR and NITROGEN atoms. Thiazole
D015738 Famotidine A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. Famotidine Hydrochloride,MK-208,Pepcid,YM-11170,MK 208,MK208,YM 11170,YM11170

Related Publications

J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
November 1978, Clinical pharmacology and therapeutics,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
September 1974, The New England journal of medicine,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
January 1991, European journal of drug metabolism and pharmacokinetics,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
September 1987, British journal of clinical pharmacology,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
September 1976, Primary care,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
October 1973, Journal of clinical pharmacology,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
August 1990, The Japanese journal of antibiotics,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
July 1994, Journal of pharmaceutical sciences,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
January 1974, The American review of respiratory disease,
J H Lin, and A N Chremos, and S M Kanovsky, and S Schwartz, and K C Yeh, and J Kann
September 1981, Acta pharmacologica et toxicologica,
Copied contents to your clipboard!